Colitis ulcerosa: Kann eine Modulation der intestinalen Mikrobiota eine langfristige Remission bedingen?

Stallmach, Andreas; Grunert, Philip; Pieper, Dietmar H.; Steube, Arndt

doi:10.1055/a-0874-6603

Cited by 4 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple case studies and several randomized trials have explored this concept in patients with IBD. While most randomized studies involving patients with UC revealed that FMT had a significant impact on induction of remission (Stallmach et al, 2019;Tan et al, 2020), its efficacy has not been verified for patients with CD. Placebo-controlled trials involving patients with UC revealed that, although one out of every 3 to 4 patients achieved remission after FMT, one-time or short-term FMT leads to clinical failure over time.…”

Section: Fecal Microbiota Transplantation: Ready For Prime Time?mentioning

confidence: 99%

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective

2021

Self Cite

View full text Add to dashboard Cite

The introduction of anti-tumor necrosis factor antibodies resulted in a considerable expansion of the options available for the treatment of inflammatory bowel disease. Unfortunately, approximately one third of treated patients do not respond to these modalities, and drug efficacy may be lost over time. These drugs are also associated with contraindications, adverse events, and intolerance. As such, there is an ongoing need for new therapeutic strategies. Despite several recent advances, including antibodies against pro-inflammatory cytokines and cell adhesion molecules, Janus kinase inhibitors, and modulators of sphingosine-1-phosphate receptors, not all problems associated with IBD have been solved. In this manuscript, we review the current state of development of several new treatment options. Ongoing evaluation will require specific proof of efficacy as well as direct comparisons with established treatments. Results from head-to-head comparisons are needed to provide clinicians with critical information on how to formulate effective therapeutic approaches for each patient.

show abstract

Section: Fecal Microbiota Transplantation: Ready For Prime Time?mentioning

confidence: 99%

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective

2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The discovery and characterization of a vast number of animal models of intestinal inflammation have greatly advanced our understanding of the pathogenesis of IBD [ 65 ]. These models have provided extensive data to support the general hypothesis that IBD results from a dysregulated immune response, triggered by environmental factors in a genetically susceptible host [ 66 ]. Innate mice provide a unique opportunity to study the influence of predisposing genes and environmental factors in the pathogenesis of IBD.…”

Section: Spontaneous Mutation Mouse Modelsmentioning

confidence: 99%

An Update of Research Animal Models of Inflammatory Bowel Disease

Baydi

Limami

Khalki

et al. 2021

The Scientific World Journal

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a group of chronic disorders that includes two main disease forms, Crohn’s disease, and ulcerative colitis. The understanding of the intestinal inflammation occurring in IBD has been immeasurably advanced by the development of the now numerous murine models of intestinal inflammation. The usefulness of this research tool in IBD arises from a convergence of underlying genetic susceptibility, immune system dysfunction, environmental factors, and shifts in gut microbiota. Due to the multifactorial feature of these diseases, different animal models have been used to investigate the underlying mechanisms and develop potential therapeutic strategies. The results of preclinical efficacy studies often inform the progression of therapeutic strategies. This review describes the distinct feature and limitations of each murine IBD model and discusses the previous and current lessons from the IBD models.

show abstract

“…In this regard, the increases of inflammatory cytokines and oxidative stress are known as important incentives to the occurrence and development of UC [5]. Furthermore, extensive studies elucidated the key role of the gut microbiota in the pathogenesis of UC, which postulated that intestinal flora disorders and the occurrence of enteritis also have a close relationship [6][7][8]. Compositional and metabolic imbalance in the intestinal microbiota could change the intestinal mucosal permeability, concomitantly with the infiltrations of pathogenic bacteria and toxins, leading to long-term inflammatory stimulation and even canceration of the colon mucosa [9,10].…”

Section: Introductionmentioning

confidence: 99%

Naringin Exhibited Therapeutic Effects against DSS-Induced Mice Ulcerative Colitis in Intestinal Barrier–Dependent Manner

Cao

Guo

et al. 2021

Molecules

View full text Add to dashboard Cite

Naringin is a kind of multi-source food additive which has been explored broadly for its various biological activities and therapeutic potential. In the present study, the protective effect and mechanism of naringin on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice were investigated. The results showed that naringin significantly alleviated DSS-induced colitis symptoms, including disease activity index (DAI), colon length shortening, and colon pathological damage. The tissue and serum secretion of inflammatory cytokines, as well as the oxidative stress, were decreased accordingly upon naringin intervention. Naringin also decreased the proteins involved in inflammation and increased the expression of tight junction (TJ) proteins. Moreover, naringin increased the relative abundance of Firmicutes/Bacteroides and reduced the content of Proteobacteria to improve the intestinal flora disorder caused by DSS, which promotes the intestinal health of mice. It was concluded that naringin can significantly ameliorate the pathogenic symptoms of UC through inhibiting inflammatory response and regulating intestinal microbiota, which might be a promising natural therapeutic agent for the dietary treatment of UC and the improvement of intestinal symbiosis.

show abstract

Colitis ulcerosa: Kann eine Modulation der intestinalen Mikrobiota eine langfristige Remission bedingen?

Cited by 4 publications

References 71 publications

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective

An Update of Research Animal Models of Inflammatory Bowel Disease

Naringin Exhibited Therapeutic Effects against DSS-Induced Mice Ulcerative Colitis in Intestinal Barrier–Dependent Manner

Contact Info

Product

Resources

About